Novo Nordisk
2012-06-21T20:02:51Z
2012-06-21T20:02:51Z
Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue
Novo Nordisk today announced the decision to initiate the global phase 3 development programme for semaglutide, a once-weekly human GLP-1 (Glucagon-Like Peptide-1) analogue.
Further information:
| Media: | Investors: |
| Mike Rulis | Kasper Roseeuw Poulsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 4303 |
| mike@novonordisk.com | krop@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ken Inchausti | Jannick Lindegaard |
| Tel: (+1) 609 514 8316 | Tel: (+1) 609 786 4575 |
| kiau@novonordisk.com | jlis@novonordisk.com |
Company announcement No 40 / 2012